56,006 trials (keyword fallback)
Mouth Neoplasms · Head and Neck Neoplasms · Tongue Neoplasms
Primary: Percent (%) Change in Levels of pS6, pAKt473, and Ki-67 — -60.60; -67.24; -31.48; 100.00 percentage of change from baseline
Head and Neck Cancer · Head and Neck Neoplasms
Primary: Number of Participants Who Experience a Pathologic Complete Response (pCR) — 0; 0 Participants
Head and Neck Neoplasms · Pheochromocytoma · Colorectal Neoplasms
Primary: Response Rate — 0; 0; 26; 11 Participants
Head and Neck Squamous Cell Carcinoma
Primary: Percentage of Patients Alive and Free of Progression at 6 Months — 27 percentage of patients
Head and Neck Cancer
Primary: Assess the Safety of the Study Drug by Calculating the Proportion of Patients Who Experience Grade 4 or 5 Study Drug Related Adverse Events, as Assessed by CTCAE v 4.03…
Anaesthesia
Primary: Oropharyngeal Leak Pressure — 25.06; 28.24; 22.88; 26.62 cm H20
Difficult Intubation
Primary: Number of Participants With Cormack-Lehane Grade >2 Obtained With CMAC D Blade — 37 Participants
Cancer of the Pharynx · Cancer of the Larynx · Cancer of the Nasal Cavity
Primary: Overall Survival: Time From Randomization to Death From Any Cause — 74.9; 72.8 percentage of participants — p=0.68
Recurrent Hypopharyngeal Squamous Cell Carcinoma · Recurrent Laryngeal Squamous Cell Carcinoma · Recurrent Laryngeal Verrucous Carcinoma
Primary: Mean Percent Change in p16 Methylation (% CpG Sites Methylated) in Tumor Tissue After Soy Isoflavone — 4.9 Percent change — p=<0.005
Head and Neck Cancer · Pharynx Cancer
Primary: Tumor Resolution — 25 Participants
Head and Neck Cancer
Primary: Percentage of Participants With Local Regional Control — 91.1 percentage of subjects
Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma · Stage II Oropharyngeal Squamous Cell Carcinoma · Stage III Hypopharyngeal Squamous Cell Carcinoma
Primary: Pathologic Complete Response Rate — 45.5 percentage of complete response
Head and Neck Basaloid Carcinoma · Recurrent Head and Neck Squamous Cell Carcinoma · Recurrent Oropharyngeal Squamous Cell Carcinoma
Primary: Progression Free Survival (PFS) — 1.8; 3.7 months — p=.04
Metastatic Squamous Cell Carcinoma of the Hypopharynx · Metastatic Squamous Cell Carcinoma of the Larynx · Metastatic Squamous Cell Carcinoma of the Oral Cavity
Primary: Progression Free Survival (PFS) — 6.08; 4.4 months
Neck Pain
Primary: Neck Pain Rating Neck Disability Index (NDI) — 13; 7.4; 12.2; 11.2 units on a scale